The United States imposed a sweeping 100% tariff on patented pharmaceutical imports on April 2, 2026, under Section 232 of the Trade Expansion Act. However, generic medicines — which make up approximately 90% of India’s pharma exports to the US — were explicitly exempted from the levy. This article breaks down what the new tariff means for Indian drug exporters, US buyers, and patients who rely on affordable generic medicines from India.
🧾 What the US Tariff Actually Says
On April 2, 2026, President Donald Trump signed a proclamation imposing a 100% ad valorem duty on patented pharmaceutical products imported into the United States. Key provisions include:
- 100% tariff on patented/innovator drugs imported into the US
- Generic medicines are exempt — the tariff does not apply to generic or biosimilar drugs
- Negotiation window — companies have 120–180 days to submit plans to relocate production to the US before tariffs take full effect
- Deal-based exemptions — major drugmakers including Merck and Eli Lilly negotiated exemptions through government pricing agreements
As reported by the BBC on April 2, 2026, “the order does not affect generic medicines, the most commonly used in the US.” Similarly, India Briefing noted that “India’s generic drugs — constituting roughly 90% of the country’s pharma exports to the US — remain untouched.”
🇮🇳 Why This Matters for India’s Generic Drug Industry
India is the world’s largest supplier of generic medicines, exporting over USD 50 billion worth of pharmaceuticals annually. The US is the single largest market, accounting for roughly 30% of India’s pharma exports. Key facts:
- 90% of India’s pharma exports to the US are generic — and therefore fully exempt from the 100% tariff, per Business Today
- Indian generic giants (Sun Pharma, Dr. Reddy’s, Cipla, Aurobindo, Lupin) face minimal direct exposure from this tariff
- Specialty/innovator players like Sun Pharma’s branded division face some exposure, as noted by Jefferies and Nomura in their April 2026 analysis
- CDMO services (contract development and manufacturing organizations) exporting innovator products may need to recalibrate their US supply chains
As Moneycontrol reported, “Generics exempt but Trump’s 100% tariffs a worry for India’s innovative pharma, CDMOs — where drugs are made will increasingly matter as much as what drugs are made.”
📉 Impact on Drug Prices in the US
The Los Angeles Times reported on April 2, 2026 that “Trump’s 100% tariffs on drugs could cost you more at the pharmacy.” However, the impact is more nuanced than a blanket price hike:
- Generic drug prices should remain stable — since generics are exempt, the 90% of US prescriptions filled with generics are unaffected
- Branded/patented drug prices may rise — innovator drugs facing the tariff could see price increases passed to patients
- Negotiated exemptions — major pharma companies that struck pricing deals with the administration avoid the levy entirely, as noted by the BBC
- Longer-term concern — the tariff signals a growing protectionist trend that could affect future policy on generic imports
For US patients importing generic medicines from India for personal use, the tariff has no direct impact — generic medicines remain duty-free. However, buyers should always verify that their supplier is a registered, GMP-compliant exporter.
🛡️ How CDSCO and WHO-GMP Compliance Protects Indian Generic Exports
India’s generic drug exports maintain their strong position in the US market because they operate under strict regulatory oversight:
- CDSCO (Central Drugs Standard Control Organization) regulates the manufacture, sale, and import/export of drugs in India
- WHO-GMP certification is required for Indian manufacturers exporting to regulated markets
- US FDA inspections — Indian generic manufacturing facilities are regularly inspected by the US FDA, and compliance is publicly tracked
- The combination of CDSCO oversight + WHO-GMP certification + US FDA facility inspections gives US buyers confidence in Indian generics
For a list of verified and reliable pharmaceutical distributors, refer to the IMSDA’s verified member directory.
🌐 What This Means for US Buyers of Indian Generics
For individual US patients and healthcare providers who purchase generic medicines from Indian suppliers:
- No price increase expected due to tariffs — generics are explicitly exempt
- Supply chain remains intact — Indian generic exports to the US continue unaffected
- CDMO/innovator exposure limited — only specialty and patented drug manufacturers face pressure
- Due diligence still essential — verify that your Indian supplier holds valid WHO-GMP certification and is registered with CDSCO
The US-India trade relationship on pharmaceuticals remains robust. In February 2026, the two countries struck an interim trade deal reducing tariffs to 18% on a range of goods, signaling continued cooperation despite the separate patented drug tariff action (India Briefing, February 11, 2026).
📋 Key Takeaways
- ✅ The 100% US tariff applies only to patented/innovator drugs — generics are exempt
- ✅ 90% of India’s pharma exports to the US are generics and unaffected
- ✅ US patients buying Indian generics face no tariff-related price increases
- ✅ Indian generic manufacturers with WHO-GMP and US FDA compliance remain strong
- ✅ Always verify your supplier through IMSDA’s member directory or CDSCO registration database
For more information, contact IMSDA at contact@indiamedicine.org.